CD44 and hepatocellular carcinoma: <b>Background/Objectives:</b> Glypican-3 (GPC3), a membrane-bound heparan sulfate proteoglycan, has been identified as a promising target for both the diagnosis and treatment of hepatocellular carcinoma (HCC).